Dąbrowski R, Smolis-Bąk E, Kowalik I et al. Heart failure medical therapy before and after left ventricular assist device implantation. Kardiol Pol. 2023.

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. Clinical and demographic characteristics

	n = 55
Age, years, mean (SD)	55.5 (10.7)
Body mass, kg, mean (SD)	84.4 (16.7)
Left ventricular ejection fraction (%), mean (SD)	15.8 (4.6)
Coronary disease, n (%)	31 (56.4)
Myocardial infarction, n (%)	28 (50.1)
Percutaneous coronary intervention, n (%)	29 (52.7)
Coronary artery bypass grafting, n (%)	6 (10.9)
Cardiomyopathy, n (%)	30 (71.4)
Valve diseases (mitral, tricuspid regurgitations), n (%)	8 (14.5)
Peripheral artery disease, n (%)	11 (20.0)
Cardioverter/defibrillator, n (%)	50 (90.9)
Cardiac resynchronisation, n (%)	11 (20.0)
Ventricular tachycardia/fibrillation, n (%)	37 (67.3)
Atrial fibrillation, n (%)	35 (63.6)
Stroke, n (%)	11 (20.0)
Arterial hypertension, n (%)	34 (68.0)
Diabetes, n (%)	21 (38.2)
Creatinine, mg/dl, median (IQR)	1.23 (0.94–1.97)
eGFR, ml/min, mean (SD)	49.1 (16.0)
Hemoglobin, g/dl, mean (SD)	10.8 (3.3)

Abbreviations: eGFR, estimated glomerular filtration rate; IQR, interquartile range; SD, standard deviation